Skip to content

Tumor mutational burden measurement from an FDA-approved assay and real-world overall survival on single-agent immune checkpoint inhibitors in over 8,000 patients across 24 cancer types

Published

May 2023

Citation

Gandara D, Agarwal N, Gupta S, Klempner S, Andrews M, Mahipal A, Subbiah V, Eskander R, Carbone D, Snider J, Bouzit L, Cho-Phan C, Price M, Li G, Quintanilha J, Huang R, Ross J, Fabrizio D, Oxnard G, Graf R. Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types. Poster presented at: 2023 ASCO Annual Meeting; June 2-6, 2023; Chicago, IL. Accessed May 25, 2023. https://meetings.asco.org/abstracts-presentations/218286 

Summary

There is ongoing debate regarding the suitability of tumor mutational burden (TMB) for use across various types of cancer and the reliability of TMB assays produced by different manufacturers. The KEYNOTE 158 trial supported the use of the Foundation Medicine test (FoundationOne®CDx, an FDA-approved TMB measurement test) for solid tumors, regardless of disease, with TMB ≥ 10 mut/Mb as a companion diagnostic for single-agent pembrolizumab in 2nd+ line treatment. To evaluate the clinical validity of the FDA-approved TMB measurement test, this study analyzed a large real-world dataset of over 8,000 patients with 24 different cancer types who received single-agent immune checkpoint inhibitors. 

Why this matters

The findings from this study can help establish the reliability of the FoundationOne®CDx test and provide valuable insights into the use of TMB as a predictive biomarker for immunotherapy in clinical practice.

Read the research

Share